1. Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical Industry Leader in Fairfield County

2. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential2 Ridgefield, Connecticut

3. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential3 Background Founded in 1885 in Ingelheim, Germany World’s largest family-owned pharmaceutical company Operates worldwide - 156 affiliated companies in over 60 countries Focus: Human Pharmaceuticals (95%) and Animal Health Products in a variety of therapeutic areas - Cardiovascular, Respiratory, CNS, Virology, Oncology, Immunology, Urology, Rheumatology, GI/Metabolic Research focused - Medicines for those diseases where genuine therapeutic innovation can be demonstrated.

4. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential4 Worldwide - 2004 Total Net Sales$ 10.2 Billion -Human Pharma96% -Animal Health 4% Total Employeesnearly 36,000 R&D+C Expenditures$ 1.23 Billion

5. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential5 Top 20 Corporations 2004 Global Pharma Market 40 35 30 25 20 15 10 5 Source: IMS Health, IMS Health / MAT Q4 2004 in EUR billion Pfizer GlaxosmithklineSanofi-AventisJohnson & Johnson Merck & Co NovartisAstrazeneca Roche Bristol-Myers SQB. Wyeth Abbott LillyAmgenTakeda Boehringer Ingelheim Schering Plough Bayer Yamanouchi-Fujisawa EisaiSchering AG 37.8 23.4 19.5 18.3 17.8 16.3 15.9 12.4 11.2 10.410.3 9.3 7.9 6.8 6.1 4.9 4.5 3.9 3.7 3.4

6. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential6 Top 20 Corporations ranked by Growth 30 25 20 15 10 5 -5 -10 -15 -20 Boehringer Ingelheim Growth Rate above Top 20 Corporations (+8.2%) MAT to Q4 2004 in Constant Euro in % Amgen Boehringer Ingelheim RocheAbbott Astrazeneca Sanofi-Aventis Wyeth Esai Johnson & Johnson Novartis Schering AGLillyTakedaPfizer Merck & Co Glaxosmithkline Yamanouchi- Fujisawa BayerBristol-Myers SQB. Schering Plough 25.5 14.3 10.2 9.4 9.2 9.0 8.4 8.0 7.3 6.46.1 5.8 4.7 3.5 1.8 -1.2 -3.9 -13.2 1.3 Source: IMS Health, IMS Health / MAT Q4 2004

7. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential7 Prescription Medicines Our Six Highlights flomax® mobic® micardis® viramune® spiriva® mirapex®

8. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential8 Ridgefield Campus Projects Lead Discovery Technologies Building dedicated in 2001 Kilo Lab Completed in 2005, produces drug substances up to 5 kg quantities for research purposes. On-site Child Care Center; September 2006 19,000 sq ft stand alone building with a capacity for 256 infants, toddlers and preschoolers. Physical Sciences building; March 2007 86,000 sq ft building to accommodate relocation of our cardiovascular diseases research program from Germany. 3 floors, 119 work stations for scientists and management.

9. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential9 BI Cares Foundation The Foundation’s mission is to improve lives through innovative philanthropic contributions and donations of healthcare products and resources. BI Cares Foundation Patient Assistance Plan (170,000 patients expected to be enrolled in 2005) Hurricane Rita and Katrina assistance Product Donation Program ($160M in product donation anticipated in 2005) Cash contributions in 2004 - $1.9M

10. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential10 Community Involvement - CT Lung Health Screening Program United Way of Northern Fairfield County Regional Hospice of Western Connecticut American Red Cross Connecticut PBS – Family Science Expo Abilities Beyond Disabilities (DATAHR) Connecticut United for Research Excellence Ives Center for the Arts Girl Scout Council of SW Connecticut Regional YMCA Center for Arts & Humanities Special Olympics – Connecticut Western Connecticut State University

11. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential11 Pharmaceutical Industry Challenges - Government Prescription drug importation AKA price controls Promotion restrictions Lower market penetration of new products Increased costs of doing business Energy, taxes, fees, liability

12. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential12 Continued innovation Continued ability to fund R&D Cost of and time to develop new products Attracting talented, highly educated workforce Continue to effectively and efficiently serve a diverse and changing marketplace Physicians, patients, institutions, payors Pharmaceutical Industry Challenges - Industry

13. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential13 Summary BI is a growing, innovative pharmaceutical company and employer in Fairfield County BI is committed to delivering value to patients and to the healthcare community Challenges to the healthcare marketplace and pharmaceutical industry are significant

14. Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential14 Web information http://www.boehringer-ingelheim.com Worldwide webhttp://www.boehringer-ingelheim.com http://us.boehringer-ingelheim.com US company webhttp://us.boehringer-ingelheim.com https://www.pparx.org/Intro.php Partnership for Prescription Assistancehttps://www.pparx.org/Intro.php http://us.boehringer- ingelheim.com/about/philanthropy/Patient_Assistance_P rogram.html BI Cares Foundation Patient Assistance webhttp://us.boehringer- ingelheim.com/about/philanthropy/Patient_Assistance_P rogram.html

15. Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical Industry Leader in Fairfield County